Characterization of portable electronic devices in physical activity of patients with rheumatic diseases

• Grant number: 23/03895-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: June 01, 2023
• End date: December 31, 2023
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Samuel Katsuyuki Shinjo
• Grantee: Nathalia Gabriele dos Santos Pereira
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Systemic autoimmune rheumatic diseases are diseases that course with an inflammatory process, that is, fever, weight loss, swelling, diffuse/joint pain and fatigue, can affect organs and systems, and are generally characterized by a high prevalence of cardiovascular diseases and morbidity, in addition to presenting a reduction in functional capacity, leading to a reduction in the level of physical activity and quality of life, specifically, in primary systemic vasculitis (PSV) showing an inflammatory process in the blood vessel, which can, among other symptoms, present intermittent claudication, as seen in Takayasu's arteritis. Systemic autoimmune myopathies (MAS) are characterized by muscle inflammation and are constantly accompanied by extramuscular manifestations, such as dermatomyositis and antisynthetase syndrome, which may affect the lungs. The use of wearable devices as telemonitoring tools and a non-pharmacological strategy for lifestyle modification and control of vital signs have gained notoriety in recent years, with a trend driven by the COVID-19 pandemic. Despite advances in the use of these devices, there are still consistent gaps regarding access, adherence, and the association of the use of wearable devices with patient-centered outcomes, such as general perception of illness, perception of fatigue and quality of life. In this context, the present study aimed to characterize wearable physical activity devices, as well as verify factors related to adherence and the association with outcomes in patients with systemic autoimmune rheumatic diseases, particularly VSP and MAS.